Which drug poses a higher risk of osteonecrosis of the jaw, risedronate or denosumab?

No direct evidence for comparing risedronate to denosumab exists; however, indirect and limited evidence indicates a potentially higher risk of osteonecrosis of the jaw with denosumab.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-10-30
DOI
https://doi.org/10.5281/zenodo.23797849
Primary Topic
Bone health and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Which drug poses a higher risk of osteonecrosis of the jaw, risedronate or denosumab?

Tripdatabase
Zenodo (CERN European Organization for Nuclear Research)
Bone health and treatments
article

Which drug poses a higher risk of osteonecrosis of the jaw, risedronate or denosumab?

Tripdatabase
article en

Abstract

No direct evidence for comparing risedronate to denosumab exists; however, indirect and limited evidence indicates a potentially higher risk of osteonecrosis of the jaw with denosumab.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 16%
Bone health and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Which drug poses a higher risk of osteonecrosis of the jaw, risedronate or denosumab? — Tripdatabase · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS